- Home
- MRKR vs BLRX Comparison
MRKR vs BLRX Comparison
Compare MRKR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- BLRX
- Stock Information
- Founded
- MRKR N/A
- BLRX 2003
- Country
- MRKR United States
- BLRX Israel
- Employees
- MRKR N/A
- BLRX N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MRKR Health Care
- BLRX Health Care
- Exchange
- MRKR Nasdaq
- BLRX Nasdaq
- Market Cap
- MRKR 30.7M
- BLRX 36.0M
- IPO Year
- MRKR N/A
- BLRX 2011
- Fundamental
- Price
- MRKR $3.47
- BLRX $0.21
- Analyst Decision
- MRKR Strong Buy
- BLRX Strong Buy
- Analyst Count
- MRKR 1
- BLRX 2
- Target Price
- MRKR $19.00
- BLRX $5.50
- AVG Volume (30 Days)
- MRKR 91.1K
- BLRX 1.7M
- Earning Date
- MRKR 11-14-2024
- BLRX 11-25-2024
- Dividend Yield
- MRKR N/A
- BLRX N/A
- EPS Growth
- MRKR N/A
- BLRX N/A
- EPS
- MRKR N/A
- BLRX N/A
- Revenue
- MRKR $5,395,849.00
- BLRX $21,991,000.00
- Revenue This Year
- MRKR $35.94
- BLRX N/A
- Revenue Next Year
- MRKR N/A
- BLRX N/A
- P/E Ratio
- MRKR N/A
- BLRX N/A
- Revenue Growth
- MRKR 79.04
- BLRX N/A
- 52 Week Low
- MRKR $2.44
- BLRX $0.19
- 52 Week High
- MRKR $6.16
- BLRX $1.68
- Technical
- Relative Strength Index (RSI)
- MRKR 50.16
- BLRX 31.98
- Support Level
- MRKR $3.47
- BLRX $0.23
- Resistance Level
- MRKR $5.95
- BLRX $0.56
- Average True Range (ATR)
- MRKR 0.63
- BLRX 0.02
- MACD
- MRKR 0.01
- BLRX 0.00
- Stochastic Oscillator
- MRKR 16.99
- BLRX 28.30
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.